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Abstract
We have recently reported that elastin microfibril interface located protein 2 (EMILIN2), an extracellular matrix
(ECM) glycoprotein, triggers cell death through a direct binding to death receptors. EMILIN2 thus influences cell
viability through a mechanism that is unique for an ECM molecule. In the present work, we report an additional
function for this molecule. First, we identify the region responsible for the proapoptotic effects, a 90-amino acid
residue-long coiled-coil fragment toward the N-terminus of the molecule. The fragment recapitulates EMILIN2
proapoptotic mechanisms. In addition, using either the full molecule or the active fragment, for the first time,
we demonstrate a significant antitumoral effect in vivo, likely due to a decrease in tumor cell viability. Unexpect-
edly, tumors treated with EMILIN2 or the deletion mutant display a significant increase of tumor angiogenesis. In
view of this novel finding, the cotreatment of the growing tumors with an antiangiogenic drug led, in most cases,
to a complete regression of tumor growth. These results grant further support to recent findings that pinpoint the
microenvironment as an important regulator of cell fate under both physiological and pathological conditions and
disclose the possibility of using EMILIN2 fragments as potent antineoplastic tools for cancer treatment.
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Introduction
Tumor growth is profoundly influenced by the neighboring cells and
microenvironment [1,2]. In this scenario, tumors represent func-
tional tissues interconnected with a large variety of cell types, blood
and lymphatic vessels, embedded in a complex network of extracel-
lular matrix (ECM) molecules composing the microenvironment,
which are thought to sustain tumor cell survival, growth, and dissem-
ination to distant organs [3]. For this reason, in the recent years, re-
searchers have focused the attention on ECM and cell components of
the microenvironment as potential targets or tools for anticancer
therapy. Endothelial cells (ECs), for instance, are promising targets
because, unlike tumor cells, they are genomically stable and thus
less prone to drug resistance. Judah Folkman [4] first foresaw the
possibility to target blood vessels instead of the tumor itself with
the aim of halting the nutrients and oxygen supply to the aberrantly
proliferating cells. These efforts have led to the discovery of many
antiangiogenetic molecules such as bevacizumab, an anti–vascular en-
dothelial growth factor (VEGF) antibody currently used in clinics in
combination with conventional chemotherapy for different types of
tumors [5–9]. In addition, tumor growth depends on the cell’s capa-
bility to proliferate and survive despite apoptotic stimuli. Resistance
to apoptosis is indeed one of the hallmarks of cancer and is achieved
through the inactivation of the finely regulated mechanisms that con-
trol this process [10,11]. Apoptosis is achieved through the initiator
caspases of the so-called intrinsic and extrinsic apoptotic pathways
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[12]. The extrinsic pathway is triggered through the engagement of
specific receptors such as DR4 (TRAIL-R1) [13] and DR5 (TRAIL-
R2) [14] by their respective death ligands [12,15]. Among these li-
gands, the tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) is a promising cancer therapeutic tool owing to its selective
action on neoplastic cells [16–18]. TRAIL binds to its receptors as a
homotrimer-inducing death receptor clustering in lipid rafts followed
by death-inducing signaling complex (DISC) assembly and caspase-8
[19] and caspase-10 activation [20].
Conversely, tumor cells receive prosurvival cues from different
constituents of the ECM through integrin receptors through which
they sense their three-dimensional location [21]. In contrast, other
ECM molecules impair cell viability. Among these proteins, CCN1
can either induce or suppress apoptosis through the integrin α6β1
and syndecan-4 [22,23]. Thrombospondin-1 stimulates apoptosis
through the CD36/p59fyn pathway [24]. Endostatin halts ECs’ via-
bility through the suppression of apoptosis inhibitors such as Bcl-2 or
through autophagy [25,26]. The secreted protein acidic and rich in
cysteine (SPARC) functions as a tumor suppressor in various cancers
[27] and induces caspase-8 activation in a death receptor–independent
manner [28], whereas decorin induces caspase-3 activation [29]. Elas-
tin microfibril interface located protein 2 (EMILIN2), a member of
the EMILIN family, is characterized by the cysteine-rich EMI domain
at the N-terminus, the hallmark of the family [30], α-helical domains
with high probability for coiled-coil structure formation and, at the
C-terminus, a proline-rich motif adjacent to a collagenous stalk preced-
ing the globular gC1q domain [31]. Recently, we have demonstrated
that EMILIN2, unique among the other ECM molecules, binds to
TRAIL receptors, leading to apoptotic cell death [32].
In this study, we discover an additional property of EMILIN2; first,
we identify the region responsible for the proapoptotic effects and dem-
onstrate that, as well as the whole molecule, it exerts a potent antineo-
plastic action in vivo. Second, we found out that EMILIN2 positively
affects tumor angiogenesis by acting on EC’s behavior and obtained a
total regression of tumor growth in combination with the anti-VEGF
antibody bevacizumab. Given that neither EMILIN2 nor bevacizumab
is toxic for normal cells, these results open the possibility to develop
novel anticancer tools with putatively limited adverse effects.
Materials and Methods
Cell Cultures
HT1080 and HeLa cell lines were from American Type Culture
Collection (ATCC, Manassas, VA) and cultured in Dulbecco’s mod-
ified Eagle medium containing 10% FBS (GIBCO BRL, Milan, Italy).
NHDF-Ad-Adult human dermal fibroblasts and human umbilical vein
endothelial cells (HUVECs) were from Lonza S.r.l. (Milan, Italy) and
were cultured in fibroblast growth medium or endothelial growth
medium, respectively; embryonic kidney cells (293-EBNA cells) were
a gift from Rupert Timpl (Max Planck, Munich, Germany) and
were cultured in Dulbecco’s modified Eagle medium containing
10% FBS and 250 μg/ml of G418 and 0.5 μg/ml of puromycin after
transfection. All cells were maintained at 37°C in a humidified 5%
CO2 atmosphere.
Antibodies and Other Reagents
The 828B3B3 anti-EMILIN2 was obtained as previously described
[32]. The anti-Δ4 polyclonal antibody was obtained after the injection
of 150 μg of the recombinant fragment in rabbit (three total boosters).
The anti–cleaved Poly(ADP-ribose) polymerase polyclonal antibody,
anti-FADD antibody, FLICE/caspase 8 fluorimetric Protease Assay Kit,
and ApopTag Apoptosis Detection Kit were from Chemicon Interna-
tional (Temecula, CA). Anti–caspase 3 and anti–type I collagen anti-
bodies were from Santa Cruz Biotechnology, Inc., Santa Cruz, CA.
The anti-DR4, anti–β-actin, anti-FLAG antibodies, the FLAG peptide,
the anti-FLAG M2 affinity gel, and the human fibronectin were from
Sigma-Aldrich S.r.l. (Milan, Italy) and Alexis (Plymouth Meeting, PA).
The secondary HRP-conjugated antibodies were from Amersham (GE
Healthcare S.r.l., Milan, Italy). The secondary antibody conjugated with
Alexa Fluor 680 was from Invitrogen S.r.l. (Milan, Italy). The anti–
histidine monoclonal antibody was from Abgent (Resnova S.r.l., Rome,
Italy). The anti–glutathione S-transferase (GST) monoclonal antibody
was from Abcam (Cambridge, MA). The Ni-NTA agarose was from
QIAGEN (Milan, Italy). The Cell Death Detection ELISAPLUS Kit
(used exclusively for the experiment in Figure 3F ) and In Situ Cell
Death Detection Fluorescein Kit were purchased from Roche Diag-
nostics S.p.A. (Milan, Italy). BD Adeno-X Rapid Titer Kit was from
BD (Buccinasco, Milan, Italy). Caspase-Glo 8 and Caspase-Glo 3/7 assays
were from Promega S.r.l. (Milan, Italy) and were used on tumor lysates
according to the manufacturer’s instructions.
DNA Constructs
EMILIN2 deletion constructs Δ1 and Δ2 were generated using the
EcoNI and NarI restriction enzymes and the available pcDNA3.1-
EMILIN2 construct [32]. Δ3 and Δ4 complementary DNA were
amplified with the following oligonucleotides: forward 5′-CTAGC-
TAGCAGACACCACTGTTAGTGGA-3′ and reverse 5′-CGGGAT-
CCTTATTCTTCA GCGTTCTTCTC-3′; forward 5′-CTAGCTA-
GCAGGCCCGCAGCCCGGGTAT-3′ and reverse 5′-CGGGAT-
CCTTAAGGCTTGGGGTGCTGGCT-3′. EMILIN2 and Δ4 were
subcloned in pDNR-CMV plasmid by the Sal I and BamHI restric-
tion enzymes. The following oligonucleotides were used: forward 5′-
CCCAAGCTTGTCGACCCACATGAGGGCCTGG ATCTTCTT-
3′ and the above two reverse oligonucleotides. Wild-type DR4 (wtDR4),
truncated DR4 mutant (tDR4), and TRAIL were reverse-transcribed
from total RNA extracted from the HeLa cell line and cloned into
pcDNA3.1/Myc-His. The following oligonucleotides were used: for-
ward 5′-CCCAAGCTTATGGCGCCACCACCAGCT-3′ and reverse
5′-TGGATATCTCTCCAAGGACACGGCAGAGC-3′; the reverse
oligonucleotide for the tDR4 was as 5′-GCTCTAGAGAGACCCAA-
GCGCCAGAA-3′. The forward oligonucleotide for TRAIL containing
a FLAG tag was 5′-CTAGCTAGCCGACTACAAGGACGACGAT-
GACAAGACCTCTGAGGAAACCATTTC-3′ and the reverse was
5′-CGTGAGCGGCCGCCAGGTCAGTTAGCCAACT-3′. The
fragment was cloned into the pCEP-Pu vector and expressed in 293-
EBNA cells. The extracellular regions of DR4 were cloned into the
pGEX-KG vector with the following oligonucleotides: forward 5′-
CGGGATCCGCGAGTGGGACAGAGGCA-3′ and reverse 5′-
GGAATT CATTATGTCCATTGCCTGA-3′.
Cell Transfection, Expression, and Purification of
Recombinant Proteins
Expression of the recombinant molecules was carried out after trans-
fection of 293-EBNA cells as previously described [32]. Proteins were
purified by means of the Ni-NTA or anti-FLAG beads. HT1080 cell
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lines were transfected using FuGene6 reagent (Roche Diagnostics
S.p.A., Milan, Italy) according to the manufacturer’s instructions.
Adenoviral Transduction
The pDNR-CMVconstructs were transferred into the Adeno-X-TRE
acceptor vector through Cre-loxP recombination. The recombination
products have been analyzed by polymerase chain reaction and enzyme
restriction. Adenovirus was produced by transfecting HEK 293 cells,
and the virus titration was determined using the Adeno-X Rapid Titer
Kit (Clontech, EuroClone S.p.a., Milan, Italy). HT1080 cells were
cotransduced with a regulatory virus (Adeno-X Tet-On; Clontech) and
the response of EMILIN2- and Δ4-recombinant viruses using 2 μg/ml
of doxycyline for induction.
Western Blot Analysis
Proteins were resolved in 4% to 20% Criterion Precast Gels (Bio-Rad
Laboratories, Milan, Italy) and transferred onto Hybond-ECL nitrocellu-
lose membranes (Amersham, GE Healthcare). Membranes were blocked
with 5% dry milk in Tris-buffered saline Tween-20, probed with the
appropriate antibodies, and the blots were developed using Enhanced
chemiluminescence (Amersham Biosciences, Cologno Monzese, Italy).
Alternatively, the Odyssey Infrared Imaging System was used (Li-COR
Biosciences, Lincoln, NE).
Analysis of DISC Assembly and GST Pull-down Assay
Immunoprecipitation of the DISC complex was carried out as previ-
ously described [32]; an equimolar amount (37.5 nM) of EMILIN2,
Δ4, TRAIL, or type I collagen was used, and the cells were incubated
for 30 minutes at 37°C. To prevent interference with the antibodies
used for immunoprecipitation, the Trueblot secondary antibody
(eBiosciences, San Diego, CA) was used. The GST pull-down assay
was carried out as previously described [32] using in vitro transcribed
and translated EMILIN2, the Δ1 and Δ4 and TRAIL, and 10 μg of
the recombinant DR4 extracellular region fused to the GST.
3-(4,5-Dimethylthiazol-2-yl)-2,5 Diphenyltetrazolium
Bromide Assays
Cells were plated in triplicates; after the different treatments, 0.3mg/ml
of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)
was added, and the cells were incubated for three extra hours. The
formazan crystals were solubilized with DMSO, and the absorbance
was detected at 620 nm.
Figure 1. EMILIN2 induces apoptosis of tumor cells, leaving normal cells unharmed. (A) Top panel: Western blot analysis of EMILIN2
expression after transduction of HT1080 cells with the adenoviral construct with or without doxycycline (Dox+ and Dox−). Bottom
panel: MTT assay after transduction. Right panels: Representative pictures of HT1080 cells undergoing apoptosis after overexpression
of EMILIN2. Bar, 75 μm. (B) MTT assays performed on HT1080 cells after treatment with 293-EBNA conditioned media in the presence
or absence of EMILIN1 or EMILIN2 (E1, E2, and CM, respectively) or with purified Multimerin2 [33] or fibronectin (MMRN2 and FN,
respectively). (C) TUNEL assay performed on HT1080 cells transduced with the EMILIN2 adenoviral construct with or without doxy-
cycline. (D) Top panel: Western blot on NHDF-Ad cells transduced with the EMILIN2 adenoviral construct with or without doxycycline.
Bottom panel: Relative MTT assay. Representative pictures of the cells are on the right panels. Bar, 75 μm. *P ≤ .02.
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Terminal Deoxynucleotide Transferase dUTP Nick End
Labeling Assays and Indirect Immunofluorescence
Apoptotic cells challenged with the various proteins were detected
with the Cell Death Detection ELISAPLUS terminal deoxynucleotide
transferase dUTP nick end labeling (TUNEL) assay. For the TUNEL
test on tumor sections, the specimens were embedded in OCT Em-
bedding Matrix (Kaltek S.r.l. Padua, Italy), and 7-μm-thick cryostat
sections were obtained using a MICRON cryostat (Heidelberg,
Germany); apoptosis was detected with the ApopTag Peroxidase
In Situ Oligo Ligation Apoptosis Detection Kit (Chemicon Interna-
tional) according to the manufacturer’s instructions. Blood vessels were
detected with an antimouse multimerin 2 monoclonal antibody that
was produced after the injection of the purified recombinant protein
in BALB/C mice [33]. Cell nuclei were stained with the TO-PRO-3
fluorescent dye (Molecular Probes, Invitrogen S.r.l.). Images were
acquired with a confocal system (Leica Microsystems, Milan, Italy).
Soft Agar Colony Assay and Three-dimensional
Matrigel Growth
Soft agar colony assays were carried out using 0.5% low-melting
agarose as previously described [32]. HT1080 cells transduced with
the Δ4 recombinant adenovirus were used in the presence or absence
of 2 μg/ml doxycycline. Alternatively, equimolar amounts of recom-
binant fibronectin or of Δ4 (37.5 nM) were added. Pictures were ob-
tained after 13 days of incubation, and the clones that formed by more
that 10 cells were counted. The assay was performed in triplicate. For
the three-dimensional Matrigel growth test, 5 × 105 HT1080 cells
transduced either with the EMILIN2 or with Δ4 were embedded in
500 μl of Matrigel (BD Biosciences Euroclone S.p.a., Milan, Italy).
Complete medium was added after solidification of the Matrigel drops
containing the cells. After 10 days, pictures were obtained.
Colony Formation Assay
Two hundred HT1080 cells per well were plated on 12-well
plates. Conditioned media from mock, EMILIN2, or Δ4 were used
in the presence of 5% FBS. After 13 days, the cells were washed with
PBS and stained with crystal violet; pictures were obtained and the
clones were counted. Alternatively, HT1080 cells were transduced
with the Δ4 adenoviral construct and were plated in the presence
or absence of doxycycline.
Cell Migration Assay
Transwells with 8-μmporemembranes (BDBiosciences, Buccinasco,
Italy) were coated with 10 μg/ml of denatured bovine serum albumin,
type I collagen, or EMILIN2, and 150 × 103 HUVECs were used for
Figure 2. The EMILIN2 proapoptotic effects are recapitulated by a 90-amino acid residue region. (A) Schematic representation of EMILIN2
(E2) and the deletion mutants (Δ1 to Δ4). The position of the amino acid residues delimiting the domains is reported at the top; those
corresponding to the deletions are at the bottom. Blue indicates EMI domain; yellow, coiled-coil region;magenta, proline-rich domain; red,
collagenous stalk; and light blue, gC1q domain. (B) Western blot analysis of the conditioned media from 293-EBNA cells transfected with
the EMILIN2 (E2), the various EMILIN2 deletions (Δ1 to Δ4), or TRAIL (T) constructs. An α-His antibody was used for the analysis, and
conditioned medium from mock-transfected cells was used as a control (CM). (C) MTT assay performed on HT1080 cells challenged with
recombinant EMILIN2 (E2), the deletion mutants (Δ1 to Δ4), or TRAIL (T). Conditioned medium (CM) from mock-transfected cells was used
as control. (D) TUNEL assay performed on HT1080 cells after treatment with EMILIN2 (E2), Δ4 (Δ4), TRAIL (T), or fibronectin (FN) as a
control. Data are representative of three independent experiments. *P ≤ .03.
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each point. Fifty nanograms per milliliter of VEGF (BD Biosystems)
was used as a chemoattractant. After 24 hours, cells were removed from
the top of the membranes, and the migrated cells on the bottom were
fixed, stained with crystal violet, and counted. Each experiment was per-
formed in triplicate and repeated three times.
Scratch Test
HUVECs cells were plated on gelatin-coated 24-well plates and, on
reaching confluence, were starved for 3 hours in serum-free medium
and scratched with a tip. Cells were then incubated with 10 μg/ml of
EMILIN2 or type I collagen in complete diluted 1:1 with serum-free
medium. Pictures were obtained over time with the Leica AF6000
Imaging System (LeicaMicrosystems). The percentage of cell migration
was evaluated measuring the area of the scratch covered by the migrated
cells by means of the Image Tool Software (http://ddsdx.uthscsa.edu/
dig/itdesc.html; San Antonio, TX). Each experiment was performed
in triplicate and repeated three times.
Tubulogenesis Assay
A total of 25 × 103 HUVECs per well were seeded on a 96-well
plate on top of presolidified Matrigel (BD Biosciences Euroclone).
Cells were treated with 2.5 μg/ml of purified recombinant EMILIN2
or Δ4; an equal volume of PBS was used as a control. Pictures were
obtained over time with the Leica AF6000 Imaging System (Leica
Microsystems). The experiment was repeated three times.
In Vivo Tumor Growth
Five BALB/c nude mice were subcutaneously injected with 1 ×
106 HT1080 cells stably transfected with pcDNA3.1 vector carrying
the luciferase or EGFP coding sequence. The animals were treated
every 3 days with 10 μg of purified EMILIN2 or Δ3 or with an equal
volume of PBS. Tumor growth was evaluated over time either using
the in vivo Imaging System (Caliper Life Sciences S.A., France) or
measuring the growing tumors with a caliper; in this case, tumor vol-
umes were calculated using the following formula: πLW 2/6, where
L indicates length and W indicates width.
Figure 3. Δ4 induces tumor cell apoptosis through direct binding to death receptor DR4. (A) Top left panel: Western blot analysis of
conditioned media from HT1080 cells transduced with the Δ4 adenoviral vector with or without doxycycline (Dox+ and Dox−, respec-
tively). Bottom left graph: MTT assay performed on HT1080 cells. Right panels: Representative image. Bar, 75 μm. (B) TUNEL assay
performed on Δ4-transduced HT1080 cells with or without doxycycline (Dox+ and Dox−, respectively). (C) GST pull-down experiment
using the DR4 extracellular region fused to the GST protein incubated with TRAIL, EMILIN2, or the Δ1 and Δ4 deletion mutants (T, E2,
Δ1, and Δ4, respectively). (D) Top panel: DISC immunoprecipitation after incubating HeLa cells with type I collagen, TRAIL, EMILIN2, or
Δ4 (C I, T, E2, and Δ4, respectively). Immunoprecipitates were analyzed with the α-type I collagen, the α-DR4, the α-caspase-8, and the
α-FADD antibodies or with α-FLAG antibody to detect EMILIN2, Δ4, or TRAIL, as indicated on the right side of the panels. Bottom panel:
Western blot analysis of caspase-8 and -3 activation showing significant decrease of the uncleaved forms after treatment with EMILIN2
and Δ4 conditioned media (E2 and Δ4, respectively). Conditioned medium (CM) from mock-transfected cells was used as control and
vinculin was used as normalizer of protein loading. (E) Right panels: Immunofluorescence analysis of caspase-8 activation after treating
HT1080 cells with Δ4 (Δ4); fibronectin and staurosporin (FN and St) were used as negative and positive controls, respectively. Left
panels: Nuclei were stained with Hoechst stain. Bar, 20 μm. (F) Left panel: ELISA-based TUNEL assay performed on HT1080 cells
transfected with a dominant-negative DR4 or with empty vector (tDR4 or mock, respectively) and challenged with Δ4. Right panel:
Schematic representation of the DR4 deletion mutant. *P ≤ .03.
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Alternatively, two groups of four animals were subcutaneously injected
with 1 × 106 EMILIN2- or EMILIN2-Δ4–transduced HT1080 cells
in the right flank and with Tet-On–transduced cells, used as a control,
in the left flank. The cell number was carefully evaluated by vital dye
exclusion (Trypan blue; Invitrogen S.r.l.); thus, a comparable number
of vital cells were injected in the different groups of animals. Drinkable
water was added with 1 mg/ml doxycycline and 2.5% sucrose, given to
the animals 2 days before tumor injection and changed every 2 days. In
other experiments, 500 μg of bevacizumab per mouse (Roche Pharma
AG, Germany) was intraperitoneally injected 2 days after cell injection.
Five other BALB/c nude mice were subcutaneously injected with
1 × 106 HT1080 cells and treated with 20 μg of purified EMILIN2
or Δ4 mutant or PBS at days 2, 5, and 9 after the implant.
Software and Instruments and Data Analysis
The graphs and statistical analysis were generated using Microsoft
Office Excel (Microsoft Italia, Segrate, Italy) and SigmaPlot software
(Systat Software Inc., San Jose, CA). Densitometric analysis was per-
formed using the Image Tool Software. Cell count and analysis of
viability were performed with Countess Automated Cell Counter and
the relative software (Invitrogen S.r.l.). In vivo imaging acquisitions
were performed using the IVIS Imaging System 100 Series (Caliper Life
Sciences). Evaluation of the light units for the luminescent substrates
was carried out with a luminometer (PerkinElmer, Inc., Waltham,MA).
Data analysis was performed using Living Image 3.0 software (Caliper
Life Sciences). All images have been assembled using Adobe Illustrator
CS and Adobe Photoshop CS (Adobe Systems Inc., San Jose, CA).
Results
Localization of the Proapoptotic Region of EMILIN2
To investigate the proapoptotic effects of EMILIN2 in detail, we
have generated an inducible adenoviral construct. This system al-
lowed an efficient expression of the molecule, which can be turned
on by the addition of doxycycline and is particularly suitable for both
in vitro and in vivo studies (Figure 1A). As expected from our previ-
ous observations [32], this approach overexpressing EMILIN2 also
led to a significant decrease in tumor cell viability, which correlated
with a dramatic increase in the cell death rate. This effect is dis-
tinctive of EMILIN2 because treatment with other members of
the family such as EMILIN1 or Multimerin2 did not affect tumor
cell viability (Figure 1B). Moreover, only cancer cells were susceptible
to the EMILIN2-driven proapoptotic activity (Figure 1C ). Transduc-
tion of normal dermal fibroblasts, among other normal cells (data not
shown), with the EMILIN2 adenoviral vector did not affect their
viability as detected by the MTT assay, confirming the results ob-
tained with another cell model [32] (Figure 1D). To determine which
region of the molecule was responsible for these effects, we have gen-
erated a series of deletion mutants (Figure 2, A and B). In this case,
the purified recombinant molecules were used to challenge HT1080
cells. As shown in Figure 2C , the Δ1 and the Δ2 deletion mutants
Figure 4. The Δ4 deletion mutant exerts an antitumoral effect in vitro. (A) Clonogenic assay performed on HT1080 cells treated with
mock, EMILIN2, or Δ4 conditioned media (CM, E2, and Δ4, respectively; left panel) or after transduction with the Δ4 adenoviral vec-
tor, with or without doxycycline (Dox+ and Dox−, respectively; right panel). Top panel: Representative pictures. (B) Soft agar colony
assay performed on HT1080 cells challenged with Δ4 or fibronectin (Δ4 and FN, respectively; left panel) or after transduction with the
Δ4 adenoviral vector, with or without doxycycline (Dox+ and Dox−, respectively; right panel). Top panel: Representative pictures. (C)
Matrigel-included HT1080 cells transduced with the EMILIN2 or Δ4 adenoviral constructs (E2 and Δ4, respectively) with or without
doxycycline (Dox+ and Dox−, respectively). Bar, 75 μm; *P ≤ .05.
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did not affect cell viability, whereas the Δ3 and the Δ4 were as ef-
fective as the whole molecule. Because the Δ4 fragment was the
smallest deletion retaining the proapoptotic activity, we have chosen
this portion for most of the subsequent analysis. This recombinant
fragment is soluble and likely preserves a proper three-dimensional
structure because it self-assembled in vitro to form homotrimers, as
demonstrated by native PAGE analysis (Figure W1). The treatment
of HT1080 cells with Δ4 led to a dramatic increase in their apop-
totic rate, comparable to that induced by the whole molecule or by
TRAIL (Figure 2D). This effect was also evident after transduction of
HT1080 cells with the Δ4 adenoviral construct (Figure 3, A and B).
The mechanism of action activated by the fragment recapitulates that
of the whole molecule described in our previous study [32]. This
fragment in fact binds to death receptor DR4 (Figure 3, C and
D), leading to receptor activation, as demonstrated by the induction
of DISC assembly followed by caspase-8 cleavage (Figure 3, D and
E ). The proapoptotic effect induced by Δ4 was abrogated by over-
expressing in HT1080 cells a dominant-negative DR4 mutant lack-
ing the cytoplasmic domain; thus, this function requires an intact
receptor (Figure 3F ).
In Vitro and In Vivo Antitumor Effects of EMILIN2 and Δ4
To determine whether the EMILIN2 and Δ4 proapoptotic effects
could lead to a decreased tumor growth in vitro, we first set up a
clonogenic assay. As shown in Figure 4A, HT1080 cells challenged
with EMILIN2 or Δ4 formed 50% less colonies in comparison with
the control. Similar results were obtained with the use of the Δ4 ad-
enoviral vector (Figure 4A, right panel ). The Δ4 fragment also halted
the number of colonies developed in soft agar either using the recom-
binant molecule or after transduction with the recombinant adeno-
virus (Figure 4B). Moreover, Δ4 impaired the growth of tumor cells
in a three-dimensional context, despite the prosurvival stimuli pro-
vided by the growth factors and ECM Matrigel components (Fig-
ure 4C ), as previously demonstrated for the entire molecule [32].
Next, to verify whether EMILIN2 could also decrease tumor growth
in vivo, EGFP-expressing HT1080 cells were injected in nude mice,
and the tumor masses were then challenged with purified recombi-
nant EMILIN2. The treatment led to a significant decrease of tumor
growth (Figure 5A). Analogous results were obtained, challenging
established tumors with recombinant EMILIN2 (Figure W2). Ac-
cordingly, overexpression of EMILIN2 after transduction with the
adenoviral vector led to a remarkable inhibition of tumor growth
(Figure 5B). Similar results were obtained treating the tumors with
recombinant Δ3 (Figure 5C ) or transducing the cells with the Δ4
adenoviral vector (Figure 5D).
Complete Regression of Tumor Growth after Treatment with
Δ4 in Combination with Bevacizumab
TUNEL assay analysis performed on the tumor sections revealed
that the tumors treated with EMILIN2 or Δ4 displayed a significant
increase in tumor cell apoptosis compared with the controls (Fig-
ure 6A). The augmented intratumoral apoptosis was prompted by
the activation of extrinsic pathway initiator caspase-8, which in turn
Figure 5. The Δ4 deletion mutant affects tumor growth in vivo. (A) In vivo imaging analysis of fluorescently labeled HT1080 tumors
treated every other day with PBS or recombinant EMILIN2 (CTRL or pE2, respectively). (B) In vivo imaging analysis of luminescent
HT1080 cells transduced with control (CTRL) or EMILIN2 (Ad-E2) adenoviral constructs and injected in the left or right flank of nude
mice, respectively. (C) In vivo imaging analysis of fluorescently labeled HT1080 tumors treated every other day with PBS or recombinant
Δ3 (CTRL or Δ3, respectively). (D) In vivo imaging analysis of luminescent HT1080 cells transduced with control adenoviral vector (CRTL)
or Δ4 construct (Ad-E2 Δ4) and injected in the left and right flank of nude mice, respectively. *P ≤ .04.
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activates the effector caspase-3/7 likely accounting for the decreased
tumor growth (Figure 6B). A more accurate analysis of the tumor
sections highlighted the presence of an increased tumor vessels den-
sity in the tumors treated with EMILIN2 or Δ4 (Figure 6C ). This
finding prompted us to investigate the efficacy of EMILIN2 and Δ4
in halting tumor growth in combination with the antiangiogenetic
antibody bevacizumab. The combination of Δ4 with bevacizumab
was strikingly more effective than either treatment alone (Figure 6D).
In most cases, a total regression of the tumors was observed, and the
tumors failed to resume growth even after the withdrawal of bevaci-
zumab treatment and of doxycycline. Only two of the treated tumors
formed small masses of approximately 2 mm3 thus allowing the ex-
cision for further analysis. As shown in Figure 6D, treatment with
bevacizumab was highly effective in reducing the Δ4-dependent ves-
sel density. The depletion of the blood vessels might likely account
for the remarkable results obtained with the combined treatment.
EMILIN2 and Δ4 Affect EC Function
The finding that tumors treated with EMILIN2 and Δ4 displayed
increased vascularization prompted us to investigate whether EMILIN2
could affect EC function. Whereas treatment with EMILIN2 or Δ4
failed to alter tubules formation in Matrigel (Figure 7A), they sig-
nificantly increased their proliferation rate (Figure 7B). In addition,
EMILIN2 was found to positively affect EC migration both in tests
performed in transwells (Figure 7B) and in scratch tests (Figure 7, C
and D). Thus, the increased EC proliferation and migration induced
Figure 6. The EMILIN2 antitumoral effects hinge on its proapoptotic effects and are enhanced by antiangiogenic combined therapy. (A)
Top panels: Representative pictures of the TUNEL assay performed on sections from tumors treated with PBS, EMILIN2, or Δ4. Bottom
graph: Evaluation of tumor cell apoptotic rate. Bar, 20 μm. (B) Caspase-8 and caspase-3/7 activity in tumors from HT1080 cells trans-
duced with the EMILIN2 or Δ4 constructs or empty vector (Ad-E2, Δ4 and CTRL, respectively), as detected by the caspase-Glo assays
(top and bottom panels, respectively). Three random tumor samples were chosen. (C) Top panels: Tumor blood vessels immunostaining
after treatment with PBS, purified EMILIN2, or Δ4 (CTRL, pE2Δ4, and pE2, respectively). Bottom graph: Evaluation of the vessel density
on 10 independent fields was performed with the Image Tool Software. Bar, 75 μm. (D) Tumor blood vessels immunostaining treatment
with bevacizumab, Δ4, or Δ4 plus bevacizumab (CTRL, BEVA, pE2Δ4, and pE2Δ4 + BEVA, respectively). Left bottom graph: Evaluation
of the vessel density. Bottom right graph: Tumor volume evaluation after injection of HT1080 cells and treatment with PBS, bevacizu-
mab, Δ4, or Δ4 plus bevacizumab (CTRL, BEVA, pE2Δ4, and pE2Δ4 + BEVA, respectively). Bar, 75 μm. The values represent the mean ±
SE of 10 tumors per point. *P ≤ .04, ×P ≤ .03, between control and treated tumors; P ≤ .02, between bevacizumab only and
bevacizumab plus Δ4.
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by EMILIN2 may likely account for the proangiogenic effects ob-
served in vivo (Figure 6C ). Taken together, these results unveil the
possibility to develop new promising tools for cancer treatment.
Discussion
In this study, we demonstrate a dual role for EMILIN2. First, we iden-
tify that the proapoptotic property resides in a region toward the N-
terminus of the molecule: the Δ4 deletion mutant encompasses the
features of the entire molecule. It binds to the DR4 receptor, inducing
DISC assembly and consequent activation of the extrinsic apoptotic
pathway, and it displays a significant antitumorigenic activity in vitro.
It is interesting to note that in analogy with TRAIL, this fragment is
homotrimeric. It is thus conceivable that it might engage death recep-
tors mimicking TRAIL three-dimensional homotrimeric structure
rather than the amino acid composition because the two molecules
have no sequence homology. In addition, in this study, for the first
time, we have analyzed the activity of EMILIN2 and Δ4 in vivo.
The adenoviral system resulted particularly useful for these studies, es-
pecially those involving combinatorial treatments because it prevented
the requirement of multiple injections. Our results indicate that tumor
growth was significantly impaired by EMILIN2 or Δ4 either over-
expressing the molecules or after treatment with the purified proteins.
It is interesting to remark that, as shown in Figure 5B, the growth of
Ad E2 cells in the first 6 days after the injection was comparable to
that of the control cells. This indicates that the exogenous EMILIN2,
which is removed after the trypsinization and washing procedures,
must be resynthesized in vivo before exerting its proapoptotic effects.
The growth impairment of the tumors challenged with Δ4 correlates
with a significant increased activation of the extrinsic apoptotic path-
way because activated caspase-8 and caspase-3/7 were enhanced in
these samples. Taken together, these observations indicate that the
EMILIN2 antitumoral properties can be primarily ascribed to its pro-
apoptotic effects. It is interesting to point out that the proapoptotic
activity exerted by this molecule was specific for tumor cells while leav-
ing normal cells unharmed. In fact, the ectopic expression of EMILIN2
or Δ4 in normal skin fibroblasts did not lead to any change in their
viability. This aspect is particularly advantageous when dealing with a
putative antineoplastic molecule such as the case of TRAIL, which, for
its specificity in killing tumor cells, has been proposed as a promising
therapeutical tool for the cure of cancer. In fact, several preclinical stud-
ies pinpoint the successes encountered with the use of this molecule
[18,34–36]. In this context, the EMILIN2Δ4 regionmay also represent
Figure 7. EMILIN2 affects EC proliferation and migration. (A) Pictures taken at four time intervals during in vitro tubulogenesis on Matrigel
after treatment with 2.5 μg/ml of recombinant EMILIN2 or Δ4; PBS was used as a control (pE2, pE2Δ4, and PBS, respectively). Bar, 75 μm.
(B) Top graph: MTT assay performed on HUVECs treated with PBS, Δ4, or EMILIN2 (CTRL, pE2Δ4, and pE2, respectively). Bottom graph:
Number of HUVEC migrated cells after transwell membrane coating with 10 μg/ml of denatured BSA, recombinant EMILIN2, or type I
collagen (BSA, pE2, and Coll I, respectively). Cells were counted in 10 fields each. (C) Scratch test performed on HUVECs treated with
10 μg/ml of recombinant EMILIN2 or type I collagen (pE2 and Coll I, respectively). Pictures were obtained at different time intervals. Bar,
75 μm. (D) The percentage of cell migration was extrapolated bymeasuring the area of the scratch covered by the migrating cells by means
of the Image Tool Software. Results represent the mean ± SD of three independent experiments. *P ≤ .04.
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a promising approach for the development of novel nontoxic therapeutic
tools. EMILIN2 is expressed by a variety of tissues during development,
and its deposition decreases in adulthood [37]. It was demonstrated to
be expressed in Ewing sarcomas and to be induced by epidermal growth
factor and insulin-like growth factor 1 [32]. However, the low or nega-
tive expression of EMILIN2 in some tumors should not preclude its
usefulness as a potential therapeutic agent. Whether the higher expres-
sion of EMILIN2 in some tumor types directly relates to their growth
rate is a matter of further investigation provided that appropriate anti-
body reagents become available.
The second aspect of our findings was that the treatment with
EMILIN2 and Δ4, despite the robust reduction of tumor growth,
led to a significant increase in the blood vessel density, as observed after
a deeper analysis of the cancer lesions. This discovery was supported by
in vitro experiments where EMILIN2 and Δ4 significantly increased
EC proliferation and motility, which likely led to the increased tu-
mor vascularization. Interestingly, the increase in motility is specifi-
cally induced on EC only because preliminary data demonstrate that
EMILIN2 impinges cell migration of different tumor cell lines (data
not shown). The molecular mechanisms, based on the increased EC
proliferation and motility induced by EMILIN2, were not investigated
here. The α4β1 integrin is a receptor for ECM molecules such as fi-
bronectin and EMILIN1 [38–40]. One possibility would be that it
may also function as a receptor for EMILIN2: this integrin is also
expressed by ECs [41], and similar to EMILIN1, EMILIN2 bares
an inserted sequence in the C1q domain that contains amino acid res-
idues compatible with an α4β1 binding site [42]. Thus, the proan-
giogenic activity of EMILIN2 might be related to integrin ligation.
However, this possibility seems unlikely because the Δ4 mutant is as
effective as the whole EMILIN2 molecule in inducing angiogenesis.
Alternatively, EMILIN2 and Δ4 might engage a still unknown cell
surface receptor. Finally, EMILIN2 and Δ4 may function as a reservoir
for cytokines that activate specific receptor tyrosine kinases at the EC
surface driving in turn the angiogenic response. The combined treat-
ment with EMILIN2 or Δ4 and bevacizumab [43,44] successfully
improved the cure rate and, in most cases, led to the complete regres-
sion of the tumors. These results indicate that the residual tumor
growth observed after the treatment with EMILIN2 or Δ4 was sus-
tained by increased tumor perfusion. It is known that VEGF, which
is recognized to display antiapoptotic effects [45], as well as its recep-
tor, is expressed by tumor cells thus establishing a positive loop of
stimulation. By removing a key prosurvival stimulus, the blockage of
VEGF with bevacizumab may shift the balance toward the proapop-
totic action of EMILIN2 and Δ4. In addition, increased blood vessel
perfusion prompted by EMILIN2/Δ4 may favor drug delivery, leading
to a paradoxical higher efficiency in blocking tumor vessel formation
by antiangiogenic or conventional cytotoxic drugs. Conversely, nor-
malization of tumor vasculature induced by antiangiogenic therapy
[46] may enhance Δ4 delivery within the tumor thus allowing a more
effective proapoptotic therapy.
In conclusion, there are at least three aspects that render the cotreat-
ment with EMILIN2 and bevacizumab particularly promising. First,
both molecules do not harm normal cells. Second, bevacizumab, de-
spite the fact that it enhances tumor hypoxia, abolishes the undesired
increase in blood vessel formation induced by EMILIN2, simulta-
neously sensitizing the cells to the EMILIN2 proapoptotic action, thus
improving the efficacy of the treatments [47]. Third, the initial in-
creased tumor perfusion induced by EMILIN2, as well as the vascu-
lature normalization induced by bevacizumab, may facilitate drug
delivery. Taken together, these results highlight a potent antitumoral
effect in vivo of a 90-residue long EMILIN2 region. Owing to the lack
of cytotoxicity for normal cells, it is conceivable that this molecule or
specific peptide encompassing the proapoptotic deletion mutant might
be applied in the future as an antitumoral agent especially in combi-
nation with antiangiogenic drugs such as bevacizumab.
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Figure W1. Native polyacrylamide gel analysis of EMILIN2 deletion
mutants Δ2 and Δ4. Because biologically active TRAIL is known to
form a homotrimer in solution [1], we investigated whether the Δ4
(MW ∼ 26 kDa) could also form homotrimers in solution. We have
thus analyzed the protein molecular weight in polyacrylamide gels
under native conditions. Besides the α-lactalbumin, carbonic an-
hydrase, chicken egg albumin, and bovine serum albumin used
as standards, we have used the Δ2 (MW∼ 27 kDa) deletion mutant
as a reference for motility because it contains a gC1q domain that
behaves as a trimer, as shown for the EMILIN1 gC1q domain [2].
After separation, the proteins were analyzed by Western blot using
the α-Penta-His mAb (QIAGEN). On native gels, the two polypep-
tides displayed a similar migration pattern, also suggesting that
the Δ4 deletion mutant forms trimers under native conditions. Be-
cause the Asp 206 to Leu 295 (Δ4) region retains the ability to tri-
merize, it is conceivable that EMILIN2 acts in a similar fashion as
the homotrimer of TRAIL, which binds to three death receptor mol-
ecules [3], leading to their activation.
Figure W2. Analysis of EMILIN2 treatment on established tumors.
To analyze the effect of EMILIN2 on established tumors, 20 nude
mice were injected in the right flank with 1 million HT1080 cells.
Once the tumors reached the volumeof approximately 15 to20mm3,
half of the mice were injected daily intratumorally with 10 μg of
EMILIN2 (E2). Control mice were treated with an equal volume of
PBS (PBS). The arrow indicates the day when the treatment was
started. The values in the graph represent the mean ± SE of the var-
ious tumor volumes measured with the caliper using the following
formula: πLW2/6, where L indicates length and W indicates width.
*P ≤ .005.
